• Prequel Prenatal Screen is a non-invasive prenatal screen (NIPS) with an industry-leading failure rate of 0.1%

  • Prequel provides patients with more accurate, actionable information identifying more trisomy cases and reducing invasive diagnostic procedures

  • Supports responsible healthcare cost management as NIPS is an economical alternative to conventional screening

    Fact Sheets and Product Info:

    Executive Summary Download PDF

    About Prenatal Screening:

    Noninvasive prenatal screening provides important information.

    Most women get reassuring results that their pregnancy is at low risk for chromosome abnormalities. However, if a screen turns up something unusual, a healthcare provider will discuss what it means and will offer a follow-up diagnostic procedure to confirm the results. This may be chorionic villus sampling (CVS) or amniocentesis.

    The Prequel Prenatal Screen is a screening test, not a diagnostic test. This means it cannot give a definitive answer as to whether or not a pregnancy is affected by a chromosome condition. To confirm positive screening results, a follow-up diagnostic test will be needed and should be discussed with the patient’s provider.

    About Prequel Prenatal Screen:

    The Prequel Prenatal Screen is a noninvasive prenatal screen that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for common chromosome abnormalities, such as Down syndrome.

    cfDNA screening has been shown to be superior to methods that use maternal age, ultrasound, and serum screening. This results in a lower false-positive rate and false-negative rate.1

    The Prequel Prenatal Screen can be ordered together with the Foresight® Carrier Screen and offered to all women, including those with high BMI, an ovum donor or a twin pregnancy.

    1. Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597.6.Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012, 119(5):890-901.

    Myriad Products